Alzheimer Disease, Biomarker in Early Diagnosis, Dementia of Alzheimer Type, Mild Cognitive Impairment, Pathology
Conditions
Keywords
Blood-based markers, Population-based, p-tau217, cross-sectional, longitudinal, NfL, Alzheimer's disease pathology
Brief summary
The goal of this observational study is to (I) study the proportion of people with Alzheimer's disease pathology in a large Norwegian population-based cohort of people aged 70 years or older and to (II) study longitudinal changes of Alzheimer's disease pathology in the same population over a 14 year period. The main aims are: * What is the proportion of people with Alzheimer's disease pathology, defined by elevated plasma p-tau217, in a large Norwegian population-based cohort of people aged 70 years or older. * What is the proportion of people with Alzheimer's disease pathology, defined by elevated plasma p-tau217, among those with normal cognition, mild cognitive impairment and dementia in a large Norwegian population-based cohort of people aged 70 years or older. * What is the association between plasma p-tau217 concentration and mild cognitive impairment or dementia 4, 10 and 14 years later, respectively. * What is the association between plasma NfL concentration and mild cognitive impairment or dementia 4, 10 and 14 years later, respectively. Data is used from The Nord-Trøndelag Health Study (HUNT) wave 3 (2006-2008) and 4 (2017 - 2019, also including HUNT AiT 2021-2023).
Interventions
None listed
Sponsors
Göteborg University
Norwegian University of Science and Technology
Helse Stavanger HF
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Living in the area of Nord-Trøndelag, where the HUNT study is carried out. * Age 70 or older when participating in HUNT4 * Available blood sample from HUNT3, HUNT4 70+ or HUNT4 70+ AiT
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma p-tau217 and NfL concentrations in the HUNT4 70+ cohort, HUNT4 AiT cohort and in selected participants from HUNT3 | Biomarker concentration was measured in plasma samples from three time points: In the year 2006-2008, year 2017-2019 and year 2021-2023. | Concentration of plasma p-tau217 measured by Alzpath217 and plasma NfL measured by Neurology 4-plex E kit. For p-tau217, we will administer a cut-off previously derived from the Wisconsin Registry for Alzheimer's Prevention study to define particpants as amyloid positive, amyloid negative or in an intermediate range. |
| Association between concentrations of plasma p-tau217 and NfL with cognitive status | Cognitive examination and blood sampling was conducted at two time points: In the year 2017-2019 and year 2021-2023. | Association between concentrations of plasma p-tau217 and NfL with a clinical diagnosis of normal cognition, MCI and dementia in the HUNT4 70+ cohort and the HUNT4 AiT cohort |
| Predictive power of plasma p-tau217 and NfL | 14 years | Reliability of plasma p-tau217 and NfL concentrations in HUNT3 and HUNT4 70+ for predicting cognitive impairment (I) measured by the MOCA in HUNT4 70+ and HUNT AiT, (II) defined by a clinical diagnosis of mild cognitive impairment or dementia in HUNT4 70+ and HUNT AiT. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Association between kidney function and plasma p-tau217 | Cross-sectional measurements at three time points: In the year 2006-2008, year 2017-2019 and year 2021-2023. And longitudinal analysis (14 years, from 2006-2008 to 2021-2023)) | What is the association between eGFR and plasma p-tau217 concentration in a large population-based cohort of older adults. |
| Prevalence of amyloid pathology in different ApoE ε genotype groups | Plasma p-tau217 was measured in plasma samples at three time points: In the year 2006-2008, year 2017-2019 and year 2021-2023. | Proportion of study participants in HUNT4 70+ and HUNT4 AiT with amyloid pathology according to plasma p-tau217 in different ApoE ε genotype groups. Proportion of participants with amyloid pathology according to plasma p-tau217 among selected study participants in HUNT3 aged 60 to 69 years at study participation, differentiated by ApoE ε genotype groups. ApoE ε genotype status in participants has already been previously established. |
Outcome results
None listed